Tema Heart & Health ETF (NASDAQ:HRTS) Sees Significant Growth in Short Interest

Tema Heart & Health ETF (NASDAQ:HRTS) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 5,158 shares, a growth of 105.7% from the August 15th total of 2,508 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 2,948 shares, the short-interest ratio is presently 1.7 days.

Tema Heart & Health ETF Trading Down 0.5%

Shares of NASDAQ:HRTS traded down $0.19 on Tuesday, reaching $36.30. The company had a trading volume of 1,225 shares, compared to its average volume of 5,756. The firm has a market capitalization of $72.56 million, a PE ratio of 22.06 and a beta of 0.63. Tema Heart & Health ETF has a 52-week low of $29.54 and a 52-week high of $38.87. The firm’s 50 day simple moving average is $37.10 and its 200-day simple moving average is $35.24.

Institutional Investors Weigh In On Tema Heart & Health ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Rothschild Capital Partners LLC acquired a new position in shares of Tema Heart & Health ETF during the second quarter worth $651,000. Royal Bank of Canada grew its stake in shares of Tema Heart & Health ETF by 8.8% during the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after acquiring an additional 1,703 shares during the last quarter. Members Advisory Group LLC acquired a new stake in Tema Heart & Health ETF in the 2nd quarter worth approximately $398,000. Anson Capital Inc. purchased a new stake in Tema Heart & Health ETF during the 2nd quarter worth approximately $297,000. Finally, XML Financial LLC acquired a new position in Tema Heart & Health ETF during the 2nd quarter valued at approximately $223,000.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.